AstraZeneca is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal.
Johnson & Johnson vowed to appeal a $4.7 billion verdict awarded to 22 women who claim asbestos-contaminated talc in the company’s products gave them ovarian cancer by arguing the plaintiffs’ science was flawed and the case should not have been heard in Missouri.
A Missouri jury ordered Johnson & Johnson to pay a record $4.69 billion to 22 women who alleged the company’s talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer.
Teva Pharmaceutical Industries Limited is moving its U.S. headquarters to Parsippany-Troy Hills, New Jersey, as part of a plan to centralize the company’s operations on the continent.
Cleara Biotech Announces Three Collaborations to Develop New Therapeutics Targeting Senescent Cells and Cancer
Cleara Biotech B.V., a Netherlands-based biopharmaceutical company, announced the creation of three public-private partnerships to discover and develop new therapeutics.
AstraZeneca suffered the company’s biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Yet now two-thirds of analysts tracked by Thomson Reuters recommend the stock, making it one of the sector’s biggest consensus buys, and CEO Pascal Soriot says he is “absolutely” happy to carry on into the 2020s as he chases early use of modern cancer drugs.
A Missouri appeals court threw out a $55 million verdict against Johnson & Johnson in a lawsuit by a woman who claimed she developed ovarian cancer after using talc-based products, including J&J’s baby powder, citing a U.S. Supreme court ruling on where such cases can be brought.
Tokyo, Japan’s capital and host of the 2020 Summer Olympics, passed a tough anti-smoking law that will effectively ban smoking in most of the city’s bars and restaurants in the run-up to the games.
China’s drug control agency on Monday said the United States should do more to cut its demand for opioids to tackle the use of the synthetic drug fentanyl, but it vowed to step up cooperation after Chinese production of the substance was blamed for fueling the U.S. opioid crisis.
Chinese companies and investors continue to flex their financial muscles with a series of deals that highlight the continued growing impact that country is having on the global pharmaceutical and biotech landscape.
Britain said it had no intention of legalizing cannabis after a former leader of Prime Minister Theresa May’s party said the government had “irreversibly lost” the battle to drive the drug off the streets.
Days after the U.S. Food and Drug Administration provided an expedited path forward for SAGE Therapeutics’ depression treatment SAGE-217, the company snagged a deal worth $575 million from Japanese pharma firm Shionogi & Co. Ltd. to market the potential drug in parts of Asia.
Kentucky’s attorney general sued Walgreens Boots Alliance Inc., accusing the company of playing a role in propagating an opioid epidemic in the state.
A lawsuit by 22 ovarian cancer patients against Johnson & Johnson went to trial in Missouri state court, marking the largest case the company has faced over allegations its talc-based products contain cancer-causing asbestos.
Britain’s Indivior was subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions.
Shortages of some life-saving antibiotics are putting growing numbers of patients at risk and fueling the evolution of “superbugs” that do not respond to modern medicines, according to a new report.
China has overtaken the United States in healthy life expectancy at birth for the first time, according to World Health Organization data.
Chinese e-commerce giant Alibaba Group Holding Ltd. will inject some of its online pharmacy business into a listed unit in a deal valued at HK$10.6 billion ($1.35 billion), the firm said in a statement.
A global coalition set up during 2017 to fight epidemics has struck a $25 million deal with two U.S. biotech companies to accelerate work on a vaccine against the brain-damaging Nipah virus that has killed 12 people in India.
Ahead of Takeda Pharmaceutical’s acquisition of Dublin-based Shire, the Japan-based company is divesting its majority stake in a Chinese joint venture for about $280 million.